COMMUNIQUÉS West-GlobeNewswire
-
Atsena Therapeutics Selects ATSN-401 Clinical Candidate, a Potential Best-in-Class Gene Therapy for Stargardt Disease
09/07/2026 -
Alignment Healthcare to Announce Second Quarter 2026 Financial Results and Host Conference Call Thursday, July 30, 2026
09/07/2026 -
UREVO Wins Red Dot Award 2026 for AI-Powered Wireless Recovery Boots, Recognized for Real-Time, AI-Adaptive Recovery
09/07/2026 -
New Data at SCCT 2026 Reinforce Heartflow Plaque Analysis as the Standard for AI-Powered Coronary Artery Disease Management
09/07/2026 -
Century Therapeutics Selected for Oral Presentations of CNTY-813 Preclinical Data at EASD 2026 and Breakthrough T1D® Clinical & Research Congress 2026
09/07/2026 -
Sam’s Club® and Weight Watchers® Collaborate to Expand Access to Affordable, Holistic Wellness Experiences for Members
09/07/2026 -
VisCardia Implants First U.S. Patient in RECOVER-HF Pivotal Trial
09/07/2026 -
Vera Therapeutics Announces Appointment of Nancy Boman as Chief Regulatory Officer and Planned Retirement of William Turner
09/07/2026 -
IN8bio Announces Publication in The Journal of Clinical Oncology Demonstrating DeltEx™ DRI Doubles Progression-Free Survival in Newly Diagnosed Glioblastoma
09/07/2026 -
SCIENTURE Announces Commercial Inventory Readiness and July Shipments of REZENOPY™ (naloxone hydrochloride) to Wholesalers
09/07/2026 -
Stereotaxis Completes Acquisition of Robocath
09/07/2026 -
Cytosurge’s CellEDIT Conquers "Impossible" Genome Engineering Challenges
09/07/2026 -
NTG Nordic Transport Group A/S - H1 2026 Conference Call
09/07/2026 -
Dysport® est la première toxine botulinique à obtenir des résultats préliminaires positifs de phase III, à la fois dans la migraine épisodique et dans la migraine chronique.
09/07/2026 -
Dysport® is the first botulinum toxin to achieve positive topline Phase III results in both episodic and chronic migraine.
09/07/2026 -
Roche receives CE Mark for blood test to identify tuberculosis infection
09/07/2026 -
New German expert consensus provides first risk-based recommendations for sNPWT use in closed surgical incisions
09/07/2026 -
New German expert consensus highlights role for NPWT in mitigating the economic impact of postoperative wound complications
09/07/2026 -
Rhythm Pharmaceuticals Announces The New England Journal of Medicine Publication of Phase 3 TRANSCEND Trial Results in Acquired Hypothalamic Obesity
08/07/2026
Pages